Japan Drug Makers Join Trend Of Outsourcing Trials, Other Work
This article was originally published in PharmAsia News
Executive Summary
Japanese drug makers are joining the trend of outsourcing clinical trials to other countries. Daiichi Sankyo is moving its first trials to India beginning next month even though foreign tests cannot be used for drug approvals in Japan. But Daiichi Sankyo says trials are cheaper in India where the population is adopting Western eating habits, making them more suitable for drugs to be marketed in Western countries. Astellas Pharma plans trials in South Korea and Eisai is exporting clinical research work to Singapore and development in other Asian nations, particularly China and India. Smaller Japanese pharmas also are looking to join the trend. (Click here for more - a subscription may be required
You may also be interested in...
Japanese Pharma Looking Beyond Japan For Clinical Trials
TOKYO - Japanese pharmaceutical manufacturers are diversifying their Phase III clinical trials away from Japan to establish development footholds into fast-developing East Asia and other regions where costs are low and trial patients can be secured with ease
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.